arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

IRIDEX CORP

IRIX
$0.86 ▲ +0.04 (+5.09%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

IRIDEX CORP faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $14.9M
Dividend Yield
Revenue Growth -0.8%
Op. Margin -2.7%
ROIC -7.7%
FCF / Share $-0.08
Trailing P/E
Price / Book 3.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 4, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$11.80M
↓ -0.8%
Net Income Profit after all expenses
$-524.00K
↑ +68.9%
Operating Margin Operating profit as % of sales
-2.7%
↓ -2595.5% 20th
FCF / Share Free cash flow per share
$-0.08
↓ -19.6%
Long-Term Debt Long-term obligations
$1.00M
↓ -28.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
17
Returns
6
Financial Health
15
Cash Quality
36

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters